CION Ameerpet
T-cell lymphoma is a diverse group of non-Hodgkin lymphomas arising from T-lymphocytes. The exact subtype — from peripheral T-cell to cutaneous types — shapes everything that follows. This overview explains them clearly and how CION plans care.
T-cell lymphoma is a group of non-Hodgkin lymphomas that develop from T-lymphocytes — a type of white blood cell that normally helps the immune system fight infection. When these T-cells become cancerous, they can build up in lymph nodes, the blood, the skin, the gut or other tissues. Unlike the more common B-cell lymphomas, T-cell lymphomas are less common overall — though in India and much of Asia they make up a larger share of non-Hodgkin lymphomas than in Western countries.
The most important thing to understand is that "T-cell lymphoma" is not a single disease. It is an umbrella term for many different subtypes, each with its own behaviour, treatment and outlook. Some, like the peripheral T-cell group, mainly affect lymph nodes; others, like cutaneous T-cell lymphoma, start in the skin. The exact subtype — confirmed on a biopsy — guides the whole plan.
This overview walks through the main T-cell lymphoma types, their symptoms, how they are diagnosed and how they are treated. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
T-cell lymphomas make up only about 10–15% of all non-Hodgkin lymphomas worldwide — but they are relatively more common in Asia, including India, than in Western countries. Because they are diverse and often aggressive, an accurate subtype diagnosis on biopsy is the single most important first step. (Source: figures consistent with NCCN and ESMO non-Hodgkin lymphoma guidance; proportions vary by region and series.)
Because T-cell lymphomas are so varied, getting the exact subtype right is what separates a well-aimed plan from a generic one. CION is built around that precision.
A biopsy read by a haematopathologist, with immunohistochemistry for markers such as CD3, CD4, CD8 and CD30, and molecular tests where needed — the foundation of every T-cell lymphoma plan.
Every case is reviewed by a multidisciplinary tumour board — haematology, medical oncology and radiation oncology together — so the plan reflects the subtype, stage and your goals.
Chemotherapy, antibody and targeted therapy, radiation (IMRT), biopsy and supportive care are delivered in-house. Stem-cell transplant is coordinated through accredited partner facilities when it is the right step.
A free 45-minute consultation, a free written second opinion on your reports, and costs explained up front. Meet our lymphoma specialists or visit the lymphoma hospital page.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a T-cell lymphoma diagnosis, unsure of your exact subtype, or need a second opinion before treatment? CION's lymphoma team is here.
T-cell lymphomas divide broadly into those that mainly affect lymph nodes and blood (nodal and systemic) and those that start in the skin (cutaneous). Understanding the main t cell lymphoma types helps make sense of why treatment differs so much from one person to the next.
| Subtype | Where it starts | Typical behaviour |
|---|---|---|
| Peripheral T-cell lymphoma (PTCL) | Lymph nodes (umbrella group) | Usually aggressive; the largest single category is "not otherwise specified" |
| Angioimmunoblastic T-cell lymphoma | Lymph nodes, immune system | Aggressive; often with fever, rash and autoimmune features |
| Anaplastic large cell lymphoma (ALCL) | Lymph nodes, sometimes skin | ALK-positive form often favourable; ALK-negative more variable |
| Cutaneous T-cell lymphoma (mycosis fungoides) | Skin | Often slow-growing; early stages can be managed for years |
| Sézary syndrome | Skin and blood | Advanced, leukaemic form of cutaneous disease; more aggressive |
| Extranodal NK/T-cell lymphoma (nasal type) | Nose, sinuses, midface | Aggressive; linked to Epstein-Barr virus |
| Lymphoblastic lymphoma | Thymus, chest, marrow | Aggressive; often in younger patients; overlaps with leukaemia |
| Breast implant-associated ALCL | Fluid/scar around a breast implant | Rare; usually treatable, often with implant removal |
Behaviour and outlook vary by individual; this table is a general guide. Subtyping follows the current WHO classification and NCCN/ESMO guidance, confirmed on biopsy.
Peripheral T-cell lymphoma (PTCL) is the most common umbrella category of nodal T-cell lymphoma. "Peripheral" refers to the fact that these lymphomas arise from mature T-cells that have already left the thymus — it does not describe where in the body the tumour sits. Most people with PTCL present with painless swelling of lymph nodes, and sometimes with fever, drenching night sweats and unexplained weight loss (the "B symptoms").
PTCL is itself a family. The largest slice is "PTCL, not otherwise specified", diagnosed when a tumour does not fit a more specific entity. Other members include angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma. Because most PTCL subtypes are aggressive and fast-growing, a prompt biopsy, accurate subtyping and an early treatment plan matter. For the full treatment pathway, see Lymphoma Treatment in Hyderabad.
Symptoms depend heavily on the subtype and where the disease is. Nodal and systemic types often show up as swollen glands and whole-body symptoms; cutaneous types show up on the skin. Common warning signs include:
These symptoms have many ordinary causes and most are not lymphoma. But anything new, persistent and unexplained — especially a lymph node that keeps growing, or a skin patch that will not clear — deserves a proper check. Speak to a CION lymphoma specialist if you have these signs or a confirmed T-cell lymphoma.
Diagnosing a T-cell lymphoma — and pinning down the exact subtype — takes a careful, step-by-step pathway. CION delivers the biopsy coordination, laboratory testing, staging scans and multidisciplinary review directly.
The diagnosis is confirmed on a tissue sample — usually a whole affected lymph node, or a skin, tissue or bone-marrow sample depending on where the disease is. A specialist haematopathologist examines the tissue under the microscope to identify the lymphoma and its likely subtype.
This is the step that separates T-cell from B-cell lymphoma and names the subtype. Immunohistochemistry reads T-cell markers such as CD3, CD4, CD8 and CD30, while molecular tests — for example T-cell receptor gene rearrangement — add confirmation. The CD30 marker also matters because it can open the door to antibody-based targeted therapy. NCCN and ESMO guidelines expect this detailed subtyping before the plan is finalised.
Once the subtype is known, staging maps how far the disease has spread using PET-CT and, for many subtypes, a bone-marrow examination. Blood tests and, for some subtypes, viral testing (such as for Epstein-Barr virus) complete the picture. Together these decide the stage and shape the treatment plan.
The CD30 marker read on a T-cell lymphoma biopsy is more than a label — when a tumour is CD30-positive, it can be targeted by an antibody-based therapy directed at that marker. This is a good example of why detailed immunohistochemistry, not just a basic biopsy, is worth doing up front. (Source: consistent with NCCN and ESMO T-cell lymphoma guidance; testing and eligibility are individualised.)
The plan depends entirely on the subtype, the stage and your overall health. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set. We describe treatment here by type, not by brand names — specific regimens are individualised on our Lymphoma Treatment in Hyderabad page. The main building blocks are:
Most aggressive nodal and systemic T-cell lymphomas are treated with combination chemotherapy, delivered directly by CION's medical oncology team. The aim is to clear the lymphoma from the body and achieve remission. Supportive care to manage side effects is provided in-house throughout.
When the tumour carries a marker such as CD30, an antibody-based targeted therapy directed at that marker may be added. This class of treatment aims to attack lymphoma cells more selectively, and is delivered by CION directly.
For localised disease and for many cutaneous T-cell lymphomas, radiation therapy (IMRT) and skin-directed treatments play a central role. CION delivers precision radiation directly, shaping the beam to the affected area while sparing healthy tissue.
For selected patients, a stem-cell transplant may be considered to consolidate remission in aggressive subtypes. At CION this is coordinated through accredited partner facilities — it is not delivered in-house. Our team plans, refers and manages the surrounding care, and continues survivorship follow-up afterwards.
Survival figures vary widely by subtype and individual. Published series report roughly 60–70% survival for common aggressive B-cell lymphoma (DLBCL) and around 80–90% for Hodgkin lymphoma; several aggressive T-cell subtypes have historically done less well, while ALK-positive ALCL and early cutaneous disease do better. These are published international figures, not CION-specific statistics, and vary by stage, age and response.
T-cell lymphoma is a family of distinct diseases. Explore each subtype in depth to understand how it behaves and how it is treated:
For general lymphoma information, start at the Lymphoma hub, review the treatment pathway, or meet the lymphoma doctors who lead care at CION.
Because T-cell lymphomas are diverse and the diagnosis is nuanced, a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if the exact subtype or CD30 status has not yet been confirmed.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.T-cell lymphoma is a group of non-Hodgkin lymphomas that develop from T-lymphocytes — a type of white blood cell that is part of the immune system. In India and much of Asia, T-cell lymphomas make up a larger share of non-Hodgkin lymphomas than in Western countries. They are a diverse family: some begin in lymph nodes, others in the skin, gut or nasal area. Because "T-cell lymphoma" covers many different diseases with very different behaviour and outlook, the exact subtype — confirmed on a biopsy with immunohistochemistry and, where needed, molecular testing — guides the whole treatment plan. Care is coordinated by CION's haematology and medical-oncology team.
T-cell lymphomas divide broadly into those that mainly affect lymph nodes and blood, and those that start in the skin. Nodal and systemic types include peripheral T-cell lymphoma (the most common umbrella group), angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma. Skin-based (cutaneous) types include cutaneous T-cell lymphoma (mycosis fungoides) and its advanced form, Sézary syndrome. Other distinct entities include extranodal NK/T-cell lymphoma (nasal type), lymphoblastic lymphoma and breast implant-associated ALCL. Each behaves differently, so the subtype matters a great deal.
Peripheral T-cell lymphoma (PTCL) is not a single disease but an umbrella term for a group of mature (peripheral) T-cell lymphomas that arise from T-cells after they have matured and left the thymus. "Peripheral" refers to this mature stage, not to the location of the tumour. PTCL is usually an aggressive, fast-growing lymphoma that most often presents with enlarged lymph nodes, and sometimes with fever, weight loss and night sweats. The largest single category, "PTCL, not otherwise specified", is diagnosed when a tumour does not fit any of the more specific subtypes. Because PTCL is diverse and behaves aggressively, an accurate subtype diagnosis and a prompt, multidisciplinary treatment plan are important.
Diagnosis begins with a biopsy — usually removing a whole affected lymph node, or sampling skin, tissue or bone marrow depending on where the disease is. A specialist haematopathologist examines the tissue and uses immunohistochemistry to read T-cell markers such as CD3, CD4, CD8, CD30 and others, which distinguish T-cell lymphomas from B-cell types and pin down the subtype. Molecular and genetic tests (for example, T-cell receptor gene rearrangement) may be added. Staging then uses PET-CT and a bone-marrow examination to map how far the disease has spread. CION delivers biopsy coordination, immunohistochemistry, staging scans and multidisciplinary review directly.
Treatment depends entirely on the subtype and stage. Many aggressive nodal T-cell lymphomas are treated with combination chemotherapy, sometimes with an antibody-based (targeted) therapy directed at a marker such as CD30 when it is present. Skin-limited cutaneous types may instead be managed with skin-directed treatments and radiation. For selected patients, a stem-cell transplant is considered to consolidate remission — this is coordinated through accredited partner facilities, not delivered in-house. CION delivers chemotherapy, antibody and targeted therapy, radiation (IMRT), biopsy and supportive care directly. Specific drug regimens are individualised — see our Lymphoma Treatment in Hyderabad page and consult a specialist.
As a group, many T-cell lymphomas do behave more aggressively and can be harder to treat than common B-cell lymphomas, which is one reason accurate subtyping matters so much. But this is a generalisation, not a rule for every case. Some T-cell lymphomas — such as certain early-stage cutaneous types and ALK-positive anaplastic large cell lymphoma — can be very slow-growing or carry a favourable outlook. Others are aggressive. The behaviour depends on the specific subtype, its molecular features, the stage and your overall health. This is exactly why a precise, biopsy-confirmed diagnosis, staged with NCCN and ESMO guidance, drives the plan rather than the broad label alone.
Outlook varies widely by subtype, so a single figure can be misleading. In broad terms, several aggressive nodal T-cell lymphomas have historically carried a less favourable outlook than common B-cell lymphomas such as DLBCL (published series report roughly 60–70% survival), while some subtypes — for example ALK-positive anaplastic large cell lymphoma and early-stage cutaneous disease — do considerably better. Hodgkin lymphoma, by contrast, is highly curable (around 80–90% in published series). These figures come from published international data and vary by individual, stage, age and response to treatment; they are not CION-specific statistics. For a realistic, personalised estimate, speak to a CION lymphoma specialist.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.